Elanco Animal Health delivered robust third-quarter 2025 financial results, with total revenue reaching $1,137 million, marking a 10% year-over-year increase. The company achieved 9% organic constant currency revenue growth, primarily fueled by strong performance in its Pet Health and Farm Animal segments, particularly from new product innovations like Credelio Quattro and Zenrelia. Adjusted EBITDA increased by 21% to $198 million, and adjusted EPS rose by 46% to $0.19, demonstrating improved operational efficiency and profitability. Elanco also improved its year-end net leverage ratio target to 3.7x, reflecting strong cash generation and debt reduction efforts.

Elanco Animal Health delivered its eighth consecutive quarter of growth in Q2 2025, with revenue increasing by 5% year-over-year to $1,241 million, driven by 8% organic constant currency growth. The company reported a net income of $11 million and adjusted EPS of $0.26. Strong performance in Pet Health, particularly from new products, and increased volumes in Farm Animal segments contributed to the positive results. Elanco also improved its full-year financial outlook and net leverage ratio target.

Elanco Animal Health reported first quarter 2025 revenue of $1,193 million, a 1% decrease year-over-year but a 4% increase in organic constant currency. The company reported net income of $67 million and adjusted net income of $184 million. Reported EPS was $0.13 and adjusted EPS was $0.37. The company raised its full-year 2025 revenue guidance.

Elanco Animal Health reported Q4 2024 revenue of $1,020 million, a 1% decrease but a 4% increase on an organic constant currency basis. The company experienced a net loss of $8 million but achieved an adjusted net income of $72 million. Adjusted EBITDA stood at $177 million, representing 17.4% of revenue. The company is focused on accelerating organic constant currency revenue growth for 2025.

Elanco Animal Health reported its Q3 2024 financial results, achieving revenue of $1,030 million with 1% organic constant currency growth. The company received U.S. FDA approval for Zenrelia™ and Credelio Quattro™, and tightened its full-year 2024 financial guidance.

Elanco reported Q2 2024 financial results with revenue of $1,184 million. The company reported a net loss of $50 million, but adjusted net income was $147 million. Adjusted EBITDA was $275 million, representing 23.2% of revenue. The company has raised its full-year revenue guidance and maintained its adjusted EBITDA guidance, excluding the Aqua divestiture.

Elanco Animal Health reported first quarter 2024 financial results, with revenue of $1,205 million and a reported EPS of $0.06. The company's performance was impacted by a shift in customer purchasing related to the ERP Blackout in 2023. Elanco is updating its full year 2024 financial guidance to reflect first quarter outperformance offset by expected unfavorable impact of foreign exchange rates.

Elanco Animal Health reported a 5% increase in revenue to $1,035 million for Q4 2023, driven by its farm animal business, innovation revenue, and price growth. However, the company experienced a net loss of $141 million, and adjusted EBITDA was adversely affected by unexpected items, including the devaluation of the Argentinian peso.

Elanco Animal Health reported a revenue of $1,068 million, a 4% increase, and a net loss of $1,096 million, which included a $1,042 million non-cash goodwill impairment charge. Adjusted EPS was $0.18, and adjusted EBITDA reached $214 million. The company is updating its full-year guidance to reflect its third-quarter performance and the impact of foreign exchange rates.

Elanco Animal Health reported a 10% decrease in revenue to $1,057 million for Q2 2023, impacted by the ERP system integration. Despite this, the company raised its full-year guidance for revenue, adjusted EBITDA, and adjusted EPS, driven by strong performance in U.S. Pet Health and International Farm Animal businesses.

Elanco Animal Health reported a 3% increase in revenue to $1,257 million for Q1 2023, driven by customer purchases shifting from Q2 due to ERP integration. The company raised the bottom end of its full-year guidance, reflecting confidence in U.S. Pet Health and international poultry businesses.

Elanco Animal Health reported a revenue decrease of 11% in Q4 2022, but delivered operating cost discipline, contributing to an Adjusted EBITDA margin expansion of 90 basis points for the year. The company delivered expected submissions for two pet health potential blockbusters and added eight product approvals in major markets.

Elanco Animal Health reported a 9% decrease in revenue, but a 5% increase in adjusted EPS. The company is reducing its full year financial outlook due to foreign exchange headwinds, the global economic slowdown and continued impacts of COVID-19 lockdowns in China.

Elanco Animal Health reported a decrease in revenue for Q2 2022, but increased adjusted EBITDA and adjusted EPS due to operational efficiency. The company is reducing its full year revenue expectations due to macro factors, but expects to deliver improved margins.

Elanco Animal Health reported a decrease of 1% in revenue, totaling $1,225 million for Q1 2022, but an increase of 2% excluding the impact of foreign exchange rates. Adjusted EBITDA was $339 million, a 1% decrease compared to Q1 2021. The company is adjusting its full year guidance to account for the strengthening U.S. dollar.

Elanco Animal Health reported a decrease in revenue by 2% to $1,113 million in Q4 2021, but an increase in gross profit to $601 million. Adjusted EPS increased by 75% to $0.21 per share and adjusted EBITDA increased by 20% to $212 million.

Elanco Animal Health reported a strong third quarter in 2021, exceeding top-line growth expectations for the fourth consecutive quarter. The company is making headway toward long-term margin targets, with pro forma combined company revenue expected to increase by approximately 7 percent and adjusted EBITDA margin expected to expand by approximately 300 basis points.

Elanco Animal Health reported strong second-quarter results, driven by the inclusion of the Bayer Animal Health business and strong performance in both Pet Health and Farm Animal segments. The company raised its full-year revenue guidance for the third time and is confident in its ability to drive sustainable double-digit adjusted EBITDA and adjusted EPS growth.

Elanco's first quarter 2021 results exceeded expectations, driven by broad-based outperformance across categories and geographies. The company is updating its full year 2021 guidance, raising and tightening adjusted ranges.

Elanco Animal Health reported Q4 2020 results, which included the Bayer Animal Health business acquired on August 1, 2020. Revenue reached $1,139.7 million, driven by strong performance in U.S. Pet Health, U.S. Farm Animal, and China swine. Adjusted EPS was at the high end of the guidance range, and the company increased its full-year 2021 guidance.

Elanco's third quarter results reflect the inclusion of the Bayer Animal Health business, with revenue at the high end of guidance. The company is integrating Bayer Animal Health, targeting $100 million in synergies, and advancing its IPP strategy. Despite COVID-19 headwinds, Elanco is driving improvements in working capital and balance sheet leverage.

Elanco Animal Health reported a decrease in total revenue by 25% to $586.3 million, primarily due to channel inventory reduction and the COVID-19 pandemic. The company reported a net loss of $53.2 million, or $0.13 per diluted share.

Elanco Animal Health reported a decrease in total revenue for the first quarter of 2020, primarily due to actions taken to reduce channel inventory levels and the impact of the COVID-19 pandemic. Despite these challenges, the company's innovation, portfolio, and productivity strategy remained a focus, with strong demand in poultry and aqua, and encouraging recovery signs from China's swine industry.

Elanco Animal Health reported Q4 2019 financial results, with total revenue decreasing by 2% to $787 million. The company experienced a net loss of $9.5 million, or $0.03 per diluted share. However, core revenue, excluding strategic exits, increased by 1% at constant currency, and the company made progress with the Bayer Animal Health acquisition.